Blog
RSS FeedPosted by Michael Wonder on 02 Sep 2023
Additional COVID-19 vaccine dose recommended for adults 75 years and over
1 September 2023 - The Australian Government has accepted advice from the Australian Technical Advisory Group on Immunisation (ATAGI) that all ...
Posted by Michael Wonder on 30 Aug 2023
EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5
30 August 2023 - The EMA’s CHMP has recommended authorising an adapted Comirnaty vaccine targeting the Omicron XBB.1.5 subvariant. ...
Posted by Michael Wonder on 29 Aug 2023
Health Canada accepts Valneva’s Chikungunya vaccine license application for review
29 August 2023 - Valneva today announced that Health Canada has completed screening validation of the Company’s regulatory application for ...
Posted by Michael Wonder on 25 Aug 2023
European Commission approves Pfizer’s Abrysvo to help protect infants through maternal immunisation and older adults from RSV
24 August 2023 - Abrysvo is the first and only RSV vaccine approved in the European Union for both older ...
Posted by Michael Wonder on 22 Aug 2023
CDC, pharmacies try to speed up Covid vaccine program for the uninsured
21 August 2023 - The timing gap prompted concerns from public health experts, who fear that it would further complicate the ...
Posted by Michael Wonder on 21 Aug 2023
FDA approves first vaccine for pregnant individuals to prevent RSV in infants
21 August 2023 - Today, the US FDA approved Abrysvo (respiratory syncytial virus vaccine), the first vaccine approved for use in ...
Posted by Michael Wonder on 16 Aug 2023
PHARMAC calls for applications from the suppliers of vaccines that protect against COVID-19
16 August 2023 - PHARMAC is interested to hear from pharmaceutical suppliers who manufacture vaccines that protect against COVID-19 and ...
Posted by Michael Wonder on 14 Aug 2023
Valneva announces PDUFA date extension for Chikungunya virus vaccine candidate
14 August 2023 – Valneva today announced that the US FDA has revised the PDUFA action date for the biologics ...
Posted by Michael Wonder on 10 Aug 2023
New COVID-19 vaccine and booster shots for this fall to be available by end of September
9 August 2023 - The first new COVID-19 vaccines updated for this fall season are now expected to be available by ...
Posted by Michael Wonder on 08 Aug 2023
UKHSA unveils VDEC in ‘step change’ for UK’s growing vaccine capabilities
7 August 2023 - Vaccine Development and Evaluation Centre to be at forefront of UK’s ability to research and develop vaccines ...
Posted by Michael Wonder on 05 Aug 2023
GSK's Arexvy, the first respiratory syncytial virus vaccine for older adults approved in Canada
4 August 2023 - Approval of Arexvy was based on a comprehensive Phase III clinical trial program that showed high vaccine ...
Posted by Michael Wonder on 03 Aug 2023
US FDA approves Merck’s Ervebo (Ebola Zaire vaccine, live) for use in children 12 months of age and older
3 August 2023 - Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease. ...
Posted by Michael Wonder on 03 Aug 2023
PHARMAC secures supply of vaccines for New Zealanders
3 August 2023 - PHARMAC has confirmed supply agreements for a range of funded vaccines including those that protect against ...
Posted by Michael Wonder on 24 Jul 2023
Shingles can be deadly, so why is the vaccine only free for one year of life?
25 July 2023 - One in three people are at risk of developing shingles in their lifetime and the risk increases ...
Posted by Michael Wonder on 24 Jul 2023
First RSV vaccine to protect infants up to 6 months of age and older adults
21 July 2023 - EMA has recommended granting a marketing authorisation in the European Union for Abrysvo, a vaccine to protect ...